TM4SF5 accelerates G1/S phase progression via cytosolic p27Kip1 expression and RhoA activity

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1803, Issue 8, 2010, Pages 975-982

  Kim, Hyeonjung ^a   Kang, Minkyung ^a   Lee, Sin Ae ^a   Kwak, Tae Kyoung ^a   Jung, Oisun ^c   Lee, Hyo Jeong ^d   Kim, Sung Hoon ^d   Lee, Jung Weon ^a,b,c  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University   (South Korea)

^d Kyung Hee University   (South Korea)

Author keywords

Cancer; Cell cycle; Cytosolic p27Kip1; RhoA; Tetraspan

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; MEMBRANE PROTEIN; RETINOBLASTOMA PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSMEMBRANE 4 L SIX FAMILY MEMBER 5 PROTEIN; UNCLASSIFIED DRUG; MITOGEN ACTIVATED PROTEIN KINASE; RHO KINASE; SMALL INTERFERING RNA; TM4SF5 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL NUCLEUS; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CYTOSOL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; ENZYME ACTIVATION; GENETICS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL LINE, TUMOR; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P27; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; G1 PHASE; HUMANS; MEMBRANE PROTEINS; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; RNA, SMALL INTERFERING; S PHASE; SIGNAL TRANSDUCTION;

EID: 77953708780     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2010.04.001     Document Type: Article

References (49)

1. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J. Pathol. 2003, 200:448-464.
2. Liotta L.A., Rao C.N., Wewer U.M. Biochemical interactions of tumor cells with the basement membrane. Annu. Rev. Biochem. 1986, 55:1037-1057.
3. Guo W., Giancotti F.G. Integrin signalling during tumour progression. Nat. Rev. Mol. Cell Biol. 2004, 5:816-826.
4. Reddig P.J., Juliano R.L. Clinging to life: cell to matrix adhesion and cell survival. Cancer Metastasis Rev. 2005, 24:425-439.
5. Gavert N., Ben-Ze'ev A. Epithelial-mesenchymal transition and the invasive potential of tumors. Trends Mol. Med. 2008, 14:199-209.
6. Sung S.Y., Hsieh C.L., Wu D., Chung L.W., Johnstone P.A. Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. Curr. Probl. Cancer 2007, 31:36-100.
7. Geiger B., Spatz J.P., Bershadsky A.D. Environmental sensing through focal adhesions. Nat. Rev. Mol. Cell Biol. 2009, 10:21-33.
8. Guarino M., Rubino B., Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007, 39:305-318.
9. Evan G.I., Vousden K.H. Proliferation, cell cycle and apoptosis in cancer. Nature 2001, 411:342-348.
10. Wright M.D., Ni J., Rudy G.B. The L6 membrane proteins-a new four-transmembrane superfamily. Protein Sci. 2000, 9:1594-1600.
11. Muller-Pillasch F., Wallrapp C., Lacher U., Friess H., Buchler M., Adler G., Gress T.M. Identification of a new tumour-associated antigen TM4SF5 and its expression in human cancer. Gene 1998, 208:25-30.
12. Pascual-Le Tallec L., Dulmet E., Bertagna X., de Keyzer Y. Identification of genes associated with the corticotroph phenotype in bronchial carcinoid tumors. J. Clin. Endocrinol. Metab. 2002, 87:5015-5022.
13. Lee S.A., Lee S.Y., Cho I.H., Oh M.A., Kang E.S., Kim Y.B., Seo W.D., Choi S., Nam J.O., Tamamori-Adachi M., Kitajima S., Ye S.K., Kim S., Hwang Y.J., Kim I.S., Park K.H., Lee J.W. Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial-mesenchymal transition in human hepatocarcinoma. J. Clin. Invest. 2008, 118:1354-1366.
14. Stipp C.S., Kolesnikova T.V., Hemler M.E. Functional domains in tetraspanin proteins. Trends Biochem. Sci. 2003, 28:106-112.
15. Lee S.-Y., Kim Y.T., Lee M.-S., Kim Y.-B., Chung E., Kim S., Lee J.W. Focal adhesion and actin organization by a cross-talk of TM4SF5 with integrin α2 are regulated by serum treatment. Exp. Cell Res. 2006, 312:2983-2999.
16. Choi S., Lee S.A., Kwak T.K., Kim H.J., Lee M.J., Ye S.K., Kim S.H., Kim S., Lee J.W. Cooperation between integrin α5 and tetraspan TM4SF5 regulates VEGF-mediated angiogenic activity. Blood 2009, 113:1845-1855.
17. Lee S.A., Kim Y.M., Kwak T.K., Kim H.J., Kim S., Kim S.H., Park K.H., Cho M., Lee J.W. The extracellular loop 2 of TM4SF5 inhibits integrin α2 on hepatocytes under collagen type I environment. Carcinogenesis 2009, 30:1872-1879.
18. Erenpreisa J., Cragg M.S. Cancer: a matter of life cycle?. Cell Biol. Int. 2007, 31:1507-1510.
19. Nevins J.R. The Rb/E2F pathway and cancer. Hum. Mol. Genet. 2001, 10:699-703.
20. Gutierrez C., Ramirez-Parra E., Castellano M.M., del Pozo J.C. G(1) to S transition: more than a cell cycle engine switch. Curr. Opin. Plant Biol. 2002, 5:480-486.
21. Kim H.-P., Kim T.-Y., Lee M.-S., Jong H.-S., Kim T.-Y., Weon Lee J., Bang Y.-J. TGF-[beta]1-mediated activations of c-Src and Rac1 modulate levels of cyclins and p27Kip1 CDK inhibitor in hepatoma cells replated on fibronectin. BBA - Mol. Cell Res. 2005, 1743:151-161.
22. Liang J., Zubovitz J., Petrocelli T., Kotchetkov R., Connor M.K., Han K., Lee J.H., Ciarallo S., Catzavelos C., Beniston R., Franssen E., Slingerland J.M. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat. Med. 2002, 8:1153-1160.
23. Albanese C., Johnson J., Watanabe G., Eklund N., Vu D., Arnold A., Pestell R.G. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J. Biol. Chem. 1995, 270:23589-23597.
24. Lee M.-S., Kim T.Y., Kim Y.-B., Lee S.-Y., Ko S.-G., Jong H.-S., Kim T.-Y., Bang Y.-J., Lee J.W. The signaling network of transforming growth factor β1, protein kinase C δ and integrin underlies the spreading and invasiveness of gastric carcinoma cells. Mol. Cell. Biol. 2005, 25:6921-6936.
25. Meloche S., Pouyssegur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 2007, 26:3227-3239.
26. Ueta T., Ikeguchi M., Hirooka Y., Kaibara N., Terada T. β-catenin and cyclin D1 expression in human hepatocellular carcinoma. Oncol. Rep. 2002, 9:1197-1203.
27. Roussel M.F. Regulation of cell cycle entry and G1 progression by CSF-1. Mol. Reprod.Dev. 1997, 46:11-18.
28. Olson M.F. Contraction reaction: mechanical regulation of Rho GTPase. Trends Cell Biol. 2004, 14:111-114.
29. Kim Y.-B., Yu J., Lee S.-Y., Lee M.-S., Ko S.-G., Ye S.-K., Jong H.-S., Kim T.-Y., Bang Y.-J., Lee J.W. Cell adhesion status-dependent histone acetylation is regulated through intracellular contractility-related signaling activities. J. Biol. Chem. 2005, 280:28357-28364.
30. Ortega S., Malumbres M., Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim. Biophys. Acta 2002, 1602:73-87.
31. Gladden A.B., Diehl J.A. Location, location, location: the role of cyclin D1 nuclear localization in cancer. J. Cell. Biochem. 2005, 96:906-913.
32. Yamamoto M., Tamakawa S., Yoshie M., Yaginuma Y., Ogawa K. Neoplastic hepatocyte growth associated with cyclin D1 redistribution from the cytoplasm to the nucleus in mouse hepatocarcinogenesis. Mol. Carcinog. 2006, 45:901-913.
33. Gieni R.S., Hendzel M.J. Actin dynamics and functions in the interphase nucleus: moving toward an understanding of nuclear polymeric actin. Biochem. Cell Biol. 2009, 87:283-306.
34. Miralles F., Posern G., Zaromytidou A.I., Treisman R. Actin dynamics control SRF activity by regulation of its coactivator MAL. Cell 2003, 113:329-342.
35. Kremer B.E., Adang L.A., Macara I.G. Septins regulate actin organization and cell-cycle arrest through nuclear accumulation of NCK mediated by SOCS7. Cell 2007, 130:837-850.
36. kip1 deregulation in cancer: down-regulation or mislocalization. Cell Cycle 2002, 1:394-400.
37. Chu I.M., Hengst L., Slingerland J.M. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat. Rev. Cancer 2008, 8:253-267.
38. KIP1 in multistage colorectal carcinogenesis. Cancer Res. 1998, 58:114-122.
39. Singh S.P., Lipman J., Goldman H., Ellis F.H., Aizenman L., Cangi M.G., Signoretti S., Chiaur D.S., Pagano M., Loda M. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res. 1998, 58:1730-1735.
40. kip1 expression in a subset of malignant gliomas. Brain Tumor Pathol. 1999, 16:17-21.
41. Baldassarre G., Belletti B., Bruni P., Boccia A., Trapasso F., Pentimalli F., Barone M.V., Chiappetta G., Vento M.T., Spiezia S., Fusco A., Viglietto G. Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. J. Clin. Invest. 1999, 104:865-874.
42. Kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nat. Med. 2002, 8:1136-1144.
43. Lee M.H., Yang H.Y. Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell. Mol. Life Sci. 2001, 58:1907-1922.
44. Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J. Biol. Chem. 2002, 277:28706-28713.
45. Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev. 2004, 18:862-876.
46. Besson A., Dowdy S.F., Roberts J.M. CDK inhibitors: cell cycle regulators and beyond. Dev. Cell 2008, 14:159-169.
47. Muschel R.J., Gal A. Tetraspanin in oncogenic epithelial-mesenchymal transition. J. Clin. Invest. 2008, 118:1347-1350.
48. Welsh C.F., Roovers K., Villanueva J., Liu Y., Schwartz M.A., Assoian R.K. Timing of cyclin D1 expression within G1 phase is controlled by Rho. Nat. Cell Biol. 2001, 3:950-957.
49. Karlsson R., Pedersen E.D., Wang Z., Brakebusch C. Rho GTPase function in tumorigenesis. Biochim. Biophys. Acta 2009, 1796:91-98.